We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...

Biogen 30-Day Option Volume & Interest Snapshot Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today ...

Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show ...

Mizuho lowered the firm’s price target on Biogen (BIIB) to $207 from $251 and keeps an Outperform rating on the shares. The analyst updated ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares ...

A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus erythematosus met its primary endpoint, demonstrating significant improvement in ...

Also Read: Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial The results were shared at the American College of Rheumatology ...

Biogen is making a few changes to its C-suite. The drugmaker will bring on Bristol Myers Squibb exec Daniel Quirk as chief medical officer and head of medical affairs, a move announced one day after ...

Biogen raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new ...

Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go ...